| Autor: |
Sekeres MA; Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA. msekeres@med.miami.edu., Watts J; Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA., Radinoff A; University Hospital Sveti Ivan Rislki, Sofia, Bulgaria., Sangerman MA; Institut Català d'Oncologia-Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Hospitalet, Barcelona, Spain., Cerrano M; Department of Molecular Biotechnology and Health Sciences, Division of Hematology, University of Turin, Turin, Italy., Lopez PF; Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain., Zeidner JF; University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA., Campelo MD; University Hospital of Salamanca, IBSAL Institute for Biomedical Research of Salamanca, Salamanca, Spain., Graux C; Department of Hematology, Université Catholique de Louvain, CHU UCL Namur (Godinne site), Yvoir, Belgium., Liesveld J; The James P Wilmot Cancer Institute, University of Rochester, Rochester, NY, USA., Selleslag D; AZ Sint Jan Brugge-Oostende, Brugge, Belgium., Tzvetkov N; MHAT Dr. Georgi Stranski, Clinic of Haematology, Pleven, Bulgaria., Fram RJ; Millennium Pharmaceuticals, Inc. a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA., Zhao D; Millennium Pharmaceuticals, Inc. a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA., Bell J; Millennium Pharmaceuticals, Inc. a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA., Friedlander S; Millennium Pharmaceuticals, Inc. a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA., Faller DV; Millennium Pharmaceuticals, Inc. a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA., Adès L; AP-HP, Hôpital Saint Louis, Paris, France.; University of Paris and INSERM U944, Paris, France. |
Full text from SpringerLink